Acinetobacter Infections Treatment - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB503243078

Publication Date:

March 25, 2024

Pages:

110

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or 鈥渟pecies鈥� of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.
The global market for Acinetobacter Infections Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
In the American market, Major manufacturers include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, and Legochem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife Pharma, Shionogi, Techulon and Tetraphase Pharmaceuticals, among others. Entasis Therapeutics, Roche and Adenium Biotech are the top 3 players of Acinetobacter Infections Treatment, with about 66% market shares.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Acinetobacter Infections Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Acinetobacter Infections Treatment by region & country, by Type, and by Pipeline.
The Acinetobacter Infections Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acinetobacter Infections Treatment.
麻豆原创 Segmentation
By Company
Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals
Segment by Type:
Sulbactam
Carbapenems
Aminoglycosides
Polymyxins
Tetracyclines
Others
Segment by Pipeline
ETX2514
Nacubactam RG6080
Arenicin
VXD-001
Small Molecule Antibiotic
AR-401 mAB
LCB01-0371 (PO)
GN-4474
Antibacterial Antibody
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Acinetobacter Infections Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Acinetobacter Infections Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Acinetobacter Infections Treatment in country level. It provides sigmate data by Type, and by Pipeline for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Acinetobacter Infections Treatment Product Introduction
1.2 Global Acinetobacter Infections Treatment 麻豆原创 Size Forecast
1.3 Acinetobacter Infections Treatment 麻豆原创 Trends & Drivers
1.3.1 Acinetobacter Infections Treatment Industry Trends
1.3.2 Acinetobacter Infections Treatment 麻豆原创 Drivers & Opportunity
1.3.3 Acinetobacter Infections Treatment 麻豆原创 Challenges
1.3.4 Acinetobacter Infections Treatment 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Acinetobacter Infections Treatment Players Revenue Ranking (2023)
2.2 Global Acinetobacter Infections Treatment Revenue by Company (2019-2024)
2.3 Key Companies Acinetobacter Infections Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Acinetobacter Infections Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Acinetobacter Infections Treatment
2.6 Acinetobacter Infections Treatment 麻豆原创 Competitive Analysis
2.6.1 Acinetobacter Infections Treatment 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Acinetobacter Infections Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acinetobacter Infections Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Sulbactam
3.1.2 Carbapenems
3.1.3 Aminoglycosides
3.1.4 Polymyxins
3.1.5 Tetracyclines
3.1.6 Others
3.2 Global Acinetobacter Infections Treatment Sales Value by Type
3.2.1 Global Acinetobacter Infections Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Acinetobacter Infections Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Acinetobacter Infections Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Pipeline
4.1 Introduction by Pipeline
4.1.1 ETX2514
4.1.2 Nacubactam RG6080
4.1.3 Arenicin
4.1.4 VXD-001
4.1.5 Small Molecule Antibiotic
4.1.6 AR-401 mAB
4.1.7 LCB01-0371 (PO)
4.1.8 GN-4474
4.1.9 Antibacterial Antibody
4.1.10 Others
4.2 Global Acinetobacter Infections Treatment Sales Value by Pipeline
4.2.1 Global Acinetobacter Infections Treatment Sales Value by Pipeline (2019 VS 2023 VS 2030)
4.2.2 Global Acinetobacter Infections Treatment Sales Value, by Pipeline (2019-2030)
4.2.3 Global Acinetobacter Infections Treatment Sales Value, by Pipeline (%) (2019-2030)
5 Segmentation by Region
5.1 Global Acinetobacter Infections Treatment Sales Value by Region
5.1.1 Global Acinetobacter Infections Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Acinetobacter Infections Treatment Sales Value by Region (2019-2024)
5.1.3 Global Acinetobacter Infections Treatment Sales Value by Region (2025-2030)
5.1.4 Global Acinetobacter Infections Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Acinetobacter Infections Treatment Sales Value, 2019-2030
5.2.2 North America Acinetobacter Infections Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Acinetobacter Infections Treatment Sales Value, 2019-2030
5.3.2 Europe Acinetobacter Infections Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Acinetobacter Infections Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Acinetobacter Infections Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Acinetobacter Infections Treatment Sales Value, 2019-2030
5.5.2 South America Acinetobacter Infections Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Acinetobacter Infections Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Acinetobacter Infections Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Acinetobacter Infections Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Acinetobacter Infections Treatment Sales Value
6.3 United States
6.3.1 United States Acinetobacter Infections Treatment Sales Value, 2019-2030
6.3.2 United States Acinetobacter Infections Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Acinetobacter Infections Treatment Sales Value by Pipeline, 2023 VS 2030
6.4 Europe
6.4.1 Europe Acinetobacter Infections Treatment Sales Value, 2019-2030
6.4.2 Europe Acinetobacter Infections Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Acinetobacter Infections Treatment Sales Value by Pipeline, 2023 VS 2030
6.5 China
6.5.1 China Acinetobacter Infections Treatment Sales Value, 2019-2030
6.5.2 China Acinetobacter Infections Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Acinetobacter Infections Treatment Sales Value by Pipeline, 2023 VS 2030
6.6 Japan
6.6.1 Japan Acinetobacter Infections Treatment Sales Value, 2019-2030
6.6.2 Japan Acinetobacter Infections Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Acinetobacter Infections Treatment Sales Value by Pipeline, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Acinetobacter Infections Treatment Sales Value, 2019-2030
6.7.2 South Korea Acinetobacter Infections Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Acinetobacter Infections Treatment Sales Value by Pipeline, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Acinetobacter Infections Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Acinetobacter Infections Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Acinetobacter Infections Treatment Sales Value by Pipeline, 2023 VS 2030
6.9 India
6.9.1 India Acinetobacter Infections Treatment Sales Value, 2019-2030
6.9.2 India Acinetobacter Infections Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Acinetobacter Infections Treatment Sales Value by Pipeline, 2023 VS 2030
7 Company Profiles
7.1 Entasis Therapeutics
7.1.1 Entasis Therapeutics Profile
7.1.2 Entasis Therapeutics Main Business
7.1.3 Entasis Therapeutics Acinetobacter Infections Treatment Products, Services and Solutions
7.1.4 Entasis Therapeutics Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Entasis Therapeutics Recent Developments
7.2 Roche
7.2.1 Roche Profile
7.2.2 Roche Main Business
7.2.3 Roche Acinetobacter Infections Treatment Products, Services and Solutions
7.2.4 Roche Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Roche Recent Developments
7.3 Adenium Biotech
7.3.1 Adenium Biotech Profile
7.3.2 Adenium Biotech Main Business
7.3.3 Adenium Biotech Acinetobacter Infections Treatment Products, Services and Solutions
7.3.4 Adenium Biotech Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Vaxdyn Recent Developments
7.4 Vaxdyn
7.4.1 Vaxdyn Profile
7.4.2 Vaxdyn Main Business
7.4.3 Vaxdyn Acinetobacter Infections Treatment Products, Services and Solutions
7.4.4 Vaxdyn Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Vaxdyn Recent Developments
7.5 Hsiri Therapeutics
7.5.1 Hsiri Therapeutics Profile
7.5.2 Hsiri Therapeutics Main Business
7.5.3 Hsiri Therapeutics Acinetobacter Infections Treatment Products, Services and Solutions
7.5.4 Hsiri Therapeutics Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Hsiri Therapeutics Recent Developments
7.6 Aridis Pharmaceuticals
7.6.1 Aridis Pharmaceuticals Profile
7.6.2 Aridis Pharmaceuticals Main Business
7.6.3 Aridis Pharmaceuticals Acinetobacter Infections Treatment Products, Services and Solutions
7.6.4 Aridis Pharmaceuticals Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Aridis Pharmaceuticals Recent Developments
7.7 LegoChem Biosciences
7.7.1 LegoChem Biosciences Profile
7.7.2 LegoChem Biosciences Main Business
7.7.3 LegoChem Biosciences Acinetobacter Infections Treatment Products, Services and Solutions
7.7.4 LegoChem Biosciences Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 LegoChem Biosciences Recent Developments
7.8 Atterx Biotherapeutics
7.8.1 Atterx Biotherapeutics Profile
7.8.2 Atterx Biotherapeutics Main Business
7.8.3 Atterx Biotherapeutics Acinetobacter Infections Treatment Products, Services and Solutions
7.8.4 Atterx Biotherapeutics Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Atterx Biotherapeutics Recent Developments
7.9 Achaogen
7.9.1 Achaogen Profile
7.9.2 Achaogen Main Business
7.9.3 Achaogen Acinetobacter Infections Treatment Products, Services and Solutions
7.9.4 Achaogen Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Achaogen Recent Developments
7.10 Peptilogics
7.10.1 Peptilogics Profile
7.10.2 Peptilogics Main Business
7.10.3 Peptilogics Acinetobacter Infections Treatment Products, Services and Solutions
7.10.4 Peptilogics Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Peptilogics Recent Developments
7.11 Sealife PHARMA
7.11.1 Sealife PHARMA Profile
7.11.2 Sealife PHARMA Main Business
7.11.3 Sealife PHARMA Acinetobacter Infections Treatment Products, Services and Solutions
7.11.4 Sealife PHARMA Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.11.5 Sealife PHARMA Recent Developments
7.12 Shionogi
7.12.1 Shionogi Profile
7.12.2 Shionogi Main Business
7.12.3 Shionogi Acinetobacter Infections Treatment Products, Services and Solutions
7.12.4 Shionogi Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.12.5 Shionogi Recent Developments
7.13 Techulon
7.13.1 Techulon Profile
7.13.2 Techulon Main Business
7.13.3 Techulon Acinetobacter Infections Treatment Products, Services and Solutions
7.13.4 Techulon Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.13.5 Techulon Recent Developments
7.14 Tetraphase Pharmaceuticals
7.14.1 Tetraphase Pharmaceuticals Profile
7.14.2 Tetraphase Pharmaceuticals Main Business
7.14.3 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Products, Services and Solutions
7.14.4 Tetraphase Pharmaceuticals Acinetobacter Infections Treatment Revenue (US$ Million) & (2019-2024)
7.14.5 Tetraphase Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Acinetobacter Infections Treatment Industrial Chain
8.2 Acinetobacter Infections Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Acinetobacter Infections Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Acinetobacter Infections Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Entasis Therapeutics
Roche
Adenium Biotech
Vaxdyn
Hsiri Therapeutics
Aridis Pharmaceuticals
LegoChem Biosciences
Atterx Biotherapeutics
Achaogen
Peptilogics
Sealife PHARMA
Shionogi
Techulon
Tetraphase Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.